Thermo Fisher Scientific Obinutuzumab Monoclonal Antibody (16B7)

Applications

ELISA (ELISA)

• Tested Dilution: 0.01–1 µg/mL

Product Specifications

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second-line treatment for follicular lymphoma.

Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. It binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.

Target Information

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second-line treatment for follicular lymphoma.

Obinutuzumab binds to CD20 on B cells, triggering cell destruction through immune engagement, apoptosis activation, and complement system activation.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.